Company Filing History:
Years Active: 2006-2013
Title: Innovations of Ming-Derg Lai in RNAi and DNA Vaccine Technologies
Introduction
Ming-Derg Lai is a prominent inventor based in Tainan, Taiwan. He has made significant contributions to the fields of RNA interference (RNAi) and DNA vaccine technologies. With a total of 2 patents, his work focuses on innovative solutions for enhancing immune responses and combating tumor growth.
Latest Patents
Ming-Derg Lai's latest patents include an RNAi compound targeted to thrombospondin-1 and a DNA vaccine containing tumor-associated gene and cytokine gene. The RNAi compound is designed to inhibit the expression of thrombospondin-1, which can activate immune responses and potentially delay tumor progression. The pharmaceutical composition developed from this invention aims to provide therapeutic benefits by reducing thrombospondin-1 expression. Additionally, his DNA vaccine utilizes DNA recombination techniques to co-incorporate fragments of tumor-associated and cytokine genes into a vector. This vaccine enhances the immune response of the host, achieving therapeutic effects against tumor growth.
Career Highlights
Ming-Derg Lai is affiliated with National Cheng-kung University, where he conducts his research and development activities. His work has garnered attention for its potential applications in cancer therapy and immunology.
Collaborations
Ming-Derg Lai collaborates with notable colleagues, including Chi-Chen Lin and Shih-Shien Huang, to advance his research initiatives.
Conclusion
Ming-Derg Lai's innovative work in RNAi and DNA vaccine technologies showcases his commitment to advancing medical science. His contributions have the potential to significantly impact cancer treatment and immune response enhancement.